SPR® Therapeutics Recognized as a Top Workplace in Northeast Ohio for the Third Year in a Row
SPR Therapeutics has been honored as a Top Workplace for the third consecutive year by cleveland.com and The Plain Dealer Top Workplaces program.
Uncategorized
The American Diabetes Association Highlights Innovations in New Drug Therapies for Patients with Obesity
Findings from three studies showcase new data on the latest developments in drug therapy innovations to treat obesity including new insights on GLP-1 receptor agonists.
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab in patients with persistent or chronic primary immune thrombocytopenia, a rare immune-mediated bleeding disorder.
5 FDA Decisions to Watch in the Second Half of 2024
The next six months for the FDA are primed to be as groundbreaking as the first six, with Eli Lilly’s donanemab and Lykos Therapeutics’ MDMA-assisted PTSD therapy on the docket, among others.
5 FDA Decisions to Watch in the Second Half of 2024 Read More »
The American Diabetes Association Names Winners of Diabetes Innovation Challenge
The American Diabetes Association ® announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potential funders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers.
The American Diabetes Association Names Winners of Diabetes Innovation Challenge Read More »
What Would a Donanemab Approval Mean for Leqembi?
With an FDA adcomm supporting donanemab’s approval for Alzheimer’s disease, experts consider the future of the anti-amyloid market.
What Would a Donanemab Approval Mean for Leqembi? Read More »
FDA Action Alert: Merck, Verona, AbbVie and Rocket
The FDA is facing four big target action dates in the final week of June, including one label expansion for a bispecific antibody and another for an investigational gene therapy.
FDA Action Alert: Merck, Verona, AbbVie and Rocket Read More »
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares
Ascentage Pharma announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of American depositary shares representing its ordinary shares.
Conexiones entre neuronas mientras pensamos
Cuando decidimos emprender una acción física inmediata, como por ejemplo un instante antes de alargar la mano y apretar un botón, un complejo proceso tiene lugar en nuestro cerebro. Usando microscopía a dos fotones, unos científicos han conseguido observar un compo …
Inteligencia artificial para diagnosticar enfermedades tropicales mediante teléfono móvil
La filariasis es una enfermedad infecciosa tropical común y afecta a más de mil millones de personas a nivel mundial. Dependiendo del parásito, causa linfedema, elefantiasis, picazón y ceguera (conocida como la ceguera de los ríos). Para eliminar la filariasis como …